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Abstract
In this editorial, we briefly summarized the International Conference on Intelligent Biology and Medicine 2019 (ICIBM 2019)
that was held on June 9–11, 2019 at Columbus, Ohio, USA. We further introduced the 19 research articles included in this
supplement issue, covering four major areas, namely computational method development, genomics analysis, network-
based analysis and biomarker prediction. The selected papers perform cutting edge computational research applied to a
broad range of human diseases such as cancer, neural degenerative and chronic inflammatory disease. They also proposed
solutions for fundamental medical genomics problems range from basic data processing and quality control to functional
interpretation, biomarker and drug prediction, and database releasing.
Introduction
The International Conference on Intelligent Biology and
Medicine 2019 (ICIBM 2019) was co-hosted by the Inter-
national Association for Intelligent Biology and Medicine
(IAIBM) and the Department of Biomedical Informatics at
The Ohio State University on June 9–11, 2019 in Colum-
bus, OH. A total of 164 researchers attended the confer-
ence, of which 79 were faculty/staff and 84 were trainees.
The conference included four keynote lectures, four emi-
nent scholar talks, five tutorials and workshops, twelve
concurrent regular scientific sessions, and one poster
session. It covered a board range of topics, including but
not limited to next-generation sequencing, single cell ana-
lyses, deep learning, metabolomics, genomics, and other
omics research, systems biology, medical applications and
translational research involving high-throughput data,
computational methods and novel applications of
computational tools, and others. Among 105 original
manuscript submissions, 19 research articles of interests
to computational method development and applications
in medical genomics were selected for the ICIBM 2019
BMC Medical Genomics Supplement Issue after with
careful peer reviews. The proposed computational
methods and applications cover a broad range of biomed-
ical topics and are innovative with significant biological
and clinical implications. A more detailed summary of the
conference arrangement, scientific programs, and achieve-
ments were published elsewhere [1]. In this editorial, we
summarize the 19 selected research articles.
Summary of selected papers
Computational tool development
This supplement issue includes five papers that propose
computational methods to [1] predict circuit RNA and
disease association, [2] predict neoantigen from multi-
omics data, [3] predict cancer types via a deep learning
based model, [4] infer associations in GWAS, and [5] clas-
sify SNP data from a database of miRNA target site SNPs.
These computational resources are all substantially novel
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modeling considerations that offer new capabilities to
medical genomics research.
Li et al. developed a new computational method, namely
SIMCCDA (Speedup Inductive Matrix Completion for
CircRNA-8 Disease Associations prediction), which is the
first work that apply the recommendation system based in-
ductive matrix completion to predict circRNA-disease asso-
ciations [2]. The circRNA-disease association was modeled
by a recommendation task and solved by using speedup in-
ductive matrix completion. Three independent circRNA
disease data set and their merged one were first used to
compute circRNA sequence similarity and disease semantic
similarity. The two similarities were further combined to
predict circRNA-disease association. The method perform-
ance was validated by cross validation and application on
breast, stomach and colorectal cancer data.
Li et al. developed a novel computational workflow for
customized neoantigen prediction and selection [3]. The
workflow takes RNA-seq, genomic sequencing and cus-
tomized proteomics data as inputs and is composed by
data processing, NetMHCpan based neoantigen predic-
tion, mutant peptides filtering and selection, proteoge-
nomics and mutant peptidome data based neoantigen
filtering, and further selection of the most likely
immunogenic neoantigen by their similarity with cross
reactive microbial peptides. The method was con-
structed based on cancer cell line data but can be
applied to solid cancer study. The method was imple-
mented in a software package namely ProGeo-neo.
Mostavi et al. conducted a novel application of convo-
lutional neural network model for cancer type prediction
by using gene expression data [4]. Novel CNN designs
and convolution kernels for cancer type and normal tis-
sue type prediction were developed and compared.
Application to 33 TCGA cancer types demonstrated the
method can accurately predict tissue types before and
after excluding tissue specific genes. A new model inter-
pretation scheme was also developed to evaluate the im-
portance of each gene feature in the predictive model.
Cai et al. developed a new association test, namely
weighted Adaptive Fisher (wAF) to test the association
of common and rare SNVs and detect dense and sparse
signals in GWAS [5]. wAF is an improved version of
their past Adaptive Fisher method, which achieved com-
parable or better statistical power when comparing with
other state-of-the-art methods. Application of wAF to a
schizophrenia dataset demonstrated the method can suc-
cessfully detect thirteen disease associated gene, out of
which nine can be support by published data.
Foroughi pour et al. developed a new computational
capability to conduct binary classification based on high
dimensional SNP data [6]. Binary classification based on
SNP data is challenged by the small samples size, high
feature space of SNP data, weak effect of SNP and
possible non-linear interaction among SNPs. Based on
the theory of high dimensional model representation,
LABS-HDMR-CO was developed that produces classi-
fication rules with good prediction performance that
can take several hundred SNPs as input, and account
for their pairwise interactions. LABS-HDMR-CO is a
very fast algorithm in nature, with runtime compar-
able to a GLM with LASSO penalty. The method
evaluation suggested that high dimensional model
representation can be a suitable framework to study
SNP data as categorical variables.
Genomics analysis
Three genomics analysis are included in this supplement
issue, two utilized network-assisted methods to explore
new SNPs in multiple sclerosis and Cleft lip with/without
cleft palate, while the other focused on somatic mutations
in genetic regulatory elements in melanoma. Each of the
two genomics data based study identified significant sets
of biological and clinical associated genetic events.
Zhang et al. explored the landscape of somatic syn-
onymous mutations in genetic regulatory elements in
melanoma [7]. This study elucidated the role of somatic
synonymous mutations in genetic aetiology of melan-
oma, by focusing on mutations related to five mecha-
nisms, namely splicing regulation, transcription factor
binding, miRNA binding, codon optimality, and the
RNA second structure. Their analysis suggested that
mutational patterns of synonymous mutations in melan-
oma are mostly involved in exonic splicing regulators
near splicing sites or inside DNase I hypersensitivity sites
or non-optimal codon. This research confirmed possible
functional impact of synonymous mutations in the dis-
ease progression.
Manuel et al. conducted a network-assisted search in
two multiple sclerosis GWAS data sets to identify the
gene networks that were associated with the disease [8].
With applying their in-house method, dmGWAS (dense
module searching of GWAS), about 7500 significant net-
work modules were identified in at least one data set
and 20 were identified from both data sets. The hub
genes and functional role of each module were further
studied. Direct linking between multiple sclerosis rele-
vant biological processes, drug targets and the functions
of identified genes were observed.
Yan et al. conducted a integrative network-assisted
GWAS study of the Cleft lip with/without cleft palate
(CL/P) [9]. By using applying their in-house methods
dmGWAS (dense module searching of GWAS) and
EW_dmGWAS (Edge-Weighted dmGWAS), in a com-
bination with GWAS data, human protein-protein inter-
action network and differential gene expression were
interactively analyzed. 87 genes were consistent identi-
fied from the sample with different ancestries by
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dmGWAS, out of which 27 showed nominal significance
with CL/P. 253 and 245 module genes associated with
CL/P from European and Asian ancestry were identified
by using EW_dmGWAS. Differential expression and
functional enrichment of the identified genes were fur-
ther studied. Nine novel candidate genes involve in cell
adhesion, plasma membrane, and regulation of apoptosis
were revealed as candidate genes related to CL/P.
Network-based analysis
Four biological network based studies, including two dif-
ferential co-expression analysis and two network based
drug prediction, are included in this supplement issue.
Two studies identified variations in co-expression net-
works through different disease stages of Alzheimer’s
disease and chronic kidney disease, which can be poten-
tially used as biomarkers of disease progression. Two
novel network based drug prediction method was devel-
oped by predicting variations in signaling pathway activ-
ities in patient subgroups and applied to identify novel
drug and targets in pancreatic and ovarian cancer.
Upadhyaya et al. conducted a differential gene co-
expression analysis of gene expression data collected
from patients’ plasma samples of Alzheimer’s disease
[10]. The authors first derived co-expression networks
from the data of the patients with different progression
stage of Alzheimer’s disease, by using their in-house de-
veloped method. A modified joint graphical lasso model
was applied to fit the authors’ assumption that the co-
expression networks in consecutive disease stages are
largely similar yet with critical differences. Differential
co-expression analysis revealed the network clustering
coefficients are stable from cognitively normal to late
mild cognitive impairment stage, and further signifi-
cantly decreased in Alzheimer’s disease patients, which
can be potentially used as biomarkers for early screening
of Alzheimer’s disease.
Yu et al. conducted a differential co-expression ana-
lysis of the RNA-seq data of chronic kidney disease
(CKD) collected from patients at different disease stages
[11]. Kidney tissue samples were collected from 140 pa-
tients with five different stages of CKD and 25 health
donors for RNA-sequencing. Differential co-expression
was conducted by using the DCGL package to identify
differentially co-expressed gene pairs, modules and
rewired pathways. A global attenuation of gene co-
expression network was observed through the samples
of different CKD stages. Specifically, strong intra-
pathway correlation rewiring has been seen in the path-
ways including regulation of nuclear SMAD2/3 signaling
and signaling events mediated by focal adhesion kinase,
27 including Regulation of nuclear SMAD2/3 signaling.
The study also identified a list of vanishing hub genes
and disrupted correlations within and between key
signaling pathways, on the pathophysiological mecha-
nisms of CKD progression.
Liu et al. conducted a network based study to identify
possible drug targets in pancreatic ductal adenocarcinoma
[12]. A novel computational method namely “spectral
clustering for network-based target ranking (SCNrank)”
was developed to prioritize drug targets. Specifically,
SCNrank integrates three data sources namely gene ex-
pression data collected from normal and cancer tissue and
cancer cell line samples, protein-protein interaction net-
work and CRISPR-CAS9 screening data. A drug target
influence score was computed from a four-step approach
by computing the importance of each gene on a PPI net-
work fitted with the gene expression data. Application of
the method on pancreatic ductal adenocarcinoma identi-
fied 367 targets of FDA approved drugs, which was vali-
dated by a strong overlap between the predicted gene-
drug relationship and the known drug target information.
Zhang et al. conducted an integrative network analysis
to identify potential drug targets of ovarian cancer [13].
In their computational pipeline, a Markov Chain Monte
Carlo method was first applied to identify up-regulated
genes and potentially activated transcriptional factors in
each individual patient. The ovarian cancer patients were
further divided into three sub-groups based on the in-
ferred transcriptional factor activity level. Up-stream sig-
naling pathways of the activated transcriptional factors
in each patient group were further inferred. 66 FPD ap-
proved drugs were identified targeting on the uncovered
core signaling pathways, out of which 44 drugs have
been reported in ovarian cancer related reports. This
work developed new insights of the potential utilization
of signaling diversity and heterogeneity for therapeutic
targets and drug combination discovery.
Biomarker prediction
A substantial part of this supplement issue is composed
by biomarker predictions, including seven works with
utilizing [1] deep learning model to handle non-linear
dependency, [2] selection and [3] prediction of transcrip-
tional regulatory features, augmenting feature space by
[4] pseudo genes and [5] network features for predicting
cancer patients’ overall and disease progression free sur-
vival, and one work focused on identifying differential
alternative splicing events in HIV infected T cells. Their
novel modeling considerations achieved significantly in-
creased prediction performance comparing to classic
models and identified sets of new biomarkers.
Huang et al. developed a novel auto-encoder based
model, namely AECOX, to identify prognostic marker
genes from cohort transcriptomics data [14]. Comparing
to classic models, AECOX utilized a novel auto-encoder-
based formulation to derive non-linear features from the
transcriptomics data that can well explain the low rank
Zhang et al. BMC Medical Genomics 2020, 13(Suppl 5):47 Page 3 of 5
structure encoded in the data. AECOX achieved a high
predictive power to the patients’ prognosis. The method
was benchmarked on TCGA data and compared with
existing deep learning based prognostic marker identifica-
tion methods. This study demonstrated that deep learning
based models, which cancer better handle the non-linear
dependency between molecular and clinical features, out-
perform classic models in predicting patients’ prognosis
by using transcriptomics data.
Liu et al. developed a novel computational pipeline to
predict colon cancer prognosis by using gene expression
level of transcriptional factors [15]. Univariate Cox
regression model is first utilized to identify prognostic
predictive transcriptional factors. A random forest based
feature selection is further conducted to identify the top
prognostic predictive transcriptional factors and con-
struct an ensample model. The method was bench-
marked on a collection of 4 high quality colon cancer
gene expression data sets consisting 925 samples. A pre-
dictive model based on five transcriptional factors was
derived, which consistently achieved a high prediction
power over the four analyzed data sets analyzed.
Dong et al. developed a new computational pipeline to
identify breast cancer patients’ prognosis associated tran-
scriptional regulatory factors (TFs), by using estimated
activity level of TFs [16]. Data set specific regulon was
first inferred by using SCENIC and ENCODE ChIP-seq
data, based on which the activity level of TFs can be fur-
ther estimated. A multivariate Cox’s regression model
was computed by using the estimated activity level of
TFs with a step-wise variable selection approach. Appli-
cation of the method on TCGA breast cancer data iden-
tified 15 transcriptional regulatory factors associated
patients’ prognosis. Validations on 29 independent
microarray data sets demonstrate a high reproducibility
of this method.
Smerekanych et al. conducted a systematic identifica-
tion of gene expression, pseudogene expression, miRNA
expression, and pseudogene-gene interactions and clin-
ical factors that were predictive to breast cancer patients’
prognosis [17]. Based on a regression model with L1
penalty, the authors identified the over expression of
STXBP5, GALP and LOC387646, the up regulation of
pseudogene CTSLP8 and RPS10P20 and down regula-
tion HLA-K, the pseudogene-gene interaction between
GPS2 and GPS2P1, and the microRNA miR-3923 were
significantly associated with the overall survival of breast
cancer. The systematic search of biomarkers from multi-
omics data source offered a more precise predictive
model of patients’ survival. This study demonstrated the
potential usage of pseudogene as cancer prognosis
markers.
Adnan et al. established a comparative evaluation of
network features to predict the metastasis of breast
cancer on data collected in 12 cohorts [18]. The authors
compared several types of network features, including
gene expression and gene variations weighted by their
neighbors obtained from protein-protein interaction net-
work, and gene co-expression networks to predict breast
cancer metastasis. The underlying hypothesis of their
data augmentation approach is that a gene expression
feature weighted by other neighbor genes over a bio-
logical network may quantify the activity level of a local
part in a biological process. A univariate analysis was
first conducted to identify the features that were predict-
ive of breast cancer metastasis. An ensemble classifica-
tion was further developed using the selected network
features. A consistent improvement of prediction per-
formance using network based features was observed.
Zhang et al. conducted a pan-cancer study to demon-
strate the clinical implication of class-3 semaphorins in
the treatment of cancer [19]. By computing the differen-
tial expression of class-3 semaphorins and their associ-
ation with patients’ overall survival in 31 TCGA cancer
types, the authors identified SEMA3A, SEMA3C and
SEMA3F are consistently up-regulated and the expres-
sion of SEMA3 family members were frequently associ-
ated with patients’ prognosis in multiple cancer types. In
addition, a significant association between SEMA3 fam-
ily and immune cell infiltration has been observed. The
analysis suggested SEMA3C and SEMA3F may poten-
tially contribute to the resistance of certain drugs.
Byun et al. conducted a study of the differential alter-
native splicing in HIV infected T cells [20]. Application
of rMATs on publicly available RNA-seq data of HIV in-
fected and normal control T cell, the authors identified
427 candidate genes with differentially expressed alterna-
tive splicing exons in infected T-cells, including 20 genes
related to cell surface, 35 to kinases, and 121 to
immune-related genes. Further pathway analysis and ex-
perimental validations confirmed the biological implica-
tions of the alternative splicing genes. To the best of our
knowledge, this study is first work to systematically ex-
plore the alternative splicing events in HIV infected T
cells, which provides novel insights of possible clinical
implications of targeting the differential alternative spli-
cing events in treating the disease.
Discussion
ICIBM conferences provide a friendly forum for re-
searchers to present and publish cutting-edge biomedical
studies. Stimulated by state-of-the-art biotechnologies,
therapeutic strategies, biological hypotheses and interdis-
ciplinary capabilities, computational scientists developed
models to link biomedical data with biological hypoth-
esis from different perspectives. Here, the 16 selected
works illustrating innovative computational ideas or ap-
plications of new computational methods on important
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biomedical questions. Even though the high complexity
of some models may limit their application in a broader
domain and some observations still need further experi-
mental validations, we anticipate some of these biomed-
ical studies and computationally derived results can
contribute in real clinical applications, as is discussed in
this supplemental issue.
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